POZEN Logo
Print Page   Close Window

Press Release

POZEN to Host June 12 Webcast to Discuss Licensing Agreement with GlaxoSmithKline to Develop and Commercialize a Novel Migraine Treatment

CHAPEL HILL, N.C.--(BUSINESS WIRE)--June 12, 2003--POZEN Inc. (NASDAQ:POZN) announced that it will host a webcast at 10:00 a.m. Eastern Time on Thursday, June 12, 2003 to discuss the Company's licensing agreement with GSK to develop and commercialize a novel migraine treatment. John R. Plachetka, Pharm.D., POZEN's chairman, president and chief executive officer, and Matthew E. Czajkowski, chief financial officer, will host the presentation. The presentation will be webcast live with slides and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company developing therapeutic advancements in a cost effective manner. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. Product development efforts are focused on diseases with unmet medical needs where POZEN can improve efficacy, safety, and/or patient convenience. The company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN." For detailed company information, see POZEN's website: www.pozen.com.

CONTACT:
POZEN Inc.
Matt Czajkowski
Chief Financial Officer
919-913-1030
or
Lisa Barthelemy
Director, Investor Relations
919-913-1044